At what enterprise value was CÉFIMÉCA acquired in 2026?

You can find the full valuation details of CÉFIMÉCA on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 13.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of CÉFIMÉCA when it was acquired by OURY MEDICAL?

The exact EV/EBITDA multiple for CÉFIMÉCA is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 13.4x. Join our community for free to access full valuation data and industry trends.

When was CÉFIMÉCA acquired by OURY MEDICAL?

CÉFIMÉCA was acquired by OURY MEDICAL in 2026.

What was the revenue of CÉFIMÉCA at the time of the deal?

The revenue of CÉFIMÉCA at the time of the deal is estimated to be in the range of 5M - 25M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of CÉFIMÉCA during the acquisition?

CÉFIMÉCA's EBITDA is estimated to be in the range of 0M - 5M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the CÉFIMÉCA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the CÉFIMÉCA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://ryortho.com/2026/04/oury-medical-announces-the-acquisition-of-cefimeca-a-leading-french-manufacturer-serving-the-orthopedic-and-spinal-markets/

← DATABASE

Home Database Healthcare & PharmaCÉFIMÉCA

04/2026

CÉFIMÉCA

Acquired by

OURY MEDICAL

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics REV 5M - 25M EUR

CÉFIMÉCA acquired by OURY MEDICAL

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics REV 5M - 25M EUR

Context

The acquisition of Céfiméca by Oury Medical represents a strategic consolidation within the French orthopedic and spinal medical device market. This transaction is the fifth build-up operation completed by Oury Medical in three years, following a platform strategy initiated by its lead investors. The primary rationale behind the deal is the creation of a comprehensive "One-Stop-Shop" offering for global orthopedic clients, combining Céfiméca’s specialized expertise in precision implants with Oury Medical’s established strength in surgical instrumentation. By integrating Céfiméca’s two production sites, the enlarged group reaches a critical mass of five manufacturing facilities and over 400 employees (combined), significantly enhancing its industrial capacity. The deal aims to improve market competitiveness by reducing lead times and offering a more integrated value chain, transitioning from a traditional supplier role to a strategic partnership model. The integration of Céfiméca’s high-value implant range specifically addresses the group's objective to master both the tools and the permanent devices used in joint and spinal procedures.

CÉFIMÉCA, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (13.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Céfiméca is a specialized manufacturer of high-precision surgical instruments and orthopedic implants. Based in La Talaudière, near Saint-Étienne, the company supports a broad client base from the prototyping phase through to serial production for various joint applications. Its technical expertise centers on precision mechanics, allowing for the creation of both standard and custom instrumentation used in orthopedic and spinal surgeries. The business model is built upon high quality standards and regulatory compliance, maintaining two production sites to ensure industrial reliability. By focusing on the convergence of complex mechanical engineering and medical requirements, Céfiméca serves as a critical supplier for major global players in the healthcare sector, particularly those requiring specialized implant capabilities and technical depth in spinal surgery solutions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Other operations with CÉFIMÉCA

REFERENCES

Revenue range: 5M - 25M EUR

EBITDA range: 0M - 5M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CÉFIMÉCA by OURY MEDICAL are reserved for mynth community members. Register for free to unlock full data.

Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: céfiméca

Acquirer: oury medical